Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers. This case of Gastric Adenocarcinoma ha...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2021-11, Vol.9 (11), p.n/a
Main Authors: Limaye, Sewanti, Patil, Darshana, Akolkar, Dadasaheb, Srivastava, Navin, Patil, Revati, Apurwa, Sachin, Patil, Sanket, John, Jinumary, Gosavi, Rahul, Nesargikar, Prabhu, Kumar, Prashant, Datta, Vineet, Bose, Chirantan, Raazi, Zarrine, Srinivasan, Ajay, Datar, Rajan
Format: Article
Language:English
Subjects:
Anorexia
Ascites
Biopsy
Cancer therapies
Case Report
Case reports
Chemotherapy
combination regimen
Conflicts of interest
encyclopedic tumor analysis
Fibroblasts
gastric adenocarcinoma
Gastric cancer
Gene amplification
Growth factors
Medical imaging
Metastasis
Mutation
Patients
pazopanib
personalized cancer treatment
precision oncology
stomach cancer
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers. This case of Gastric Adenocarcinoma had progressed following failure of several prior lines of standard of care regimens. Multi‐analyte profiling of freshly biopsied tumor sample indicated FGFR3 amplification along with sensitivity of tumor cells towards various chemotherapy drugs. The patient received personalized combination regimen of Pazopanib with Gemcitabine and Pemetrexed which yielded significant regression of metastatic deposits.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.4986